AstraZeneca Finds Two More Potential Partners For Imfinzi
Combo Data At ESMO Supports Use With CD73 And NGK2A Inhibitors
Adding oleclumab and monalizumab to the PD-L1 inhibitor improved PFS, while another study showed improved real-world outcomes.
Adding oleclumab and monalizumab to the PD-L1 inhibitor improved PFS, while another study showed improved real-world outcomes.